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Abstract XRCC2 and XRCC3 proteins are structurally
and functionally related to RAD51 which play an important
role in the homologous recombination, the process fre-
quently involved in cancer transformation. In our previous
work we show that the 135G[C polymorphism (rs1801320)
of the RAD51 gene can modify the effect of the Thr241Met
polymorphism (rs861539) of the XRCC3 gene. We tested
the association between the 135G[C polymorphism of the
RAD51 gene, the Thr241Met polymorphism of the XRCC3
gene and the Arg188His polymorphism (rs3218536) of the
XRCC2 gene and colorectal cancer risk and clinicopatho-
logical parameters. Polymorphisms were evaluated by
restrictionfragment length polymorphism polymerase chain
reaction (RFLP-PCR) in 100 patients with invasive ade-
nocarcinoma of the colon and in 100 sex, age and ethnicity
matched cancer–free controls. We stratiﬁed the patients by
genotypes, tumour Duke’s and TNM stage and calculated
the linkage of each genotype with each stratum. Carriers
of Arg188Arg/Me241tMet, His188His/Thr241Thr and His
188His/G135G genotypes had an increased risk of colo-
rectal cancer occurrence (OR 5.70, 95% CI 1.10–29.5; OR
12.4, 95% CI 1.63–94.9; OR 5.88, 95% CI 1.21–28.5,
respectively). The C135C genotype decreased the risk of
colorectal cancer singly (OR 0.06, 95% CI 0.02–0.22) as
well as in combination with other two polymorphisms.
TNM and Duke’s staging were not related to any of these
polymorphisms. Our results suggest that the 135G[C
polymorphism of the RAD51 gene can be an independent
marker of colorectal cancer risk. The Thr241Met poly-
morphism of the XRCC3 gene and the Arg188His poly-
morphism of the XRCC2 gene can modify the risk of
colorectal cancer.
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Introduction
Genetic polymorphisms in homologous recombination
repair (HRR) genes, which can lead to protein haploin-
sufﬁciency have been associated with cancer risk [1]. The
RAD51, XRCC2 and XRCC3 proteins are core compo-
nents of DNA double strand breaks (DSBs) repair by HRR.
XRCC2 and XRCC3 genes are structurally and functionally
related to the RAD51 gene [2]. Cell deﬁcient with any of
these genes product are defective in homologous recom-
bination and demonstrate genomic instability [3–6]. Ham-
ster cell lines deﬁcient in XRCC2 and XRCC3 genes had an
elevated frequency of aneuploidy compared with wild-type
cells and mutant cells transfected with an appropriate
human gene [7]. XRCC2- and XRCC3-deﬁcient hamster
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somes and abnormal spindle formation [4]. CHO cell lines
defective in XRCC2 and XRCC3 had lower spontaneous
frequency of sister chromatid exchange than wild type cells
[8]. The most frequent polymorphism in the XRCC3 gene is
aC [T transition resulting in an amino acid substitution of
Thr to Met at codon 241. Carriers of the Met allele had
relatively high DNA adducts level in lymphocyte DNA,
which could be the result of lower DNA repair capacity
[9, 10]. Conﬂicting results have been published on the
association with colon cancer [9, 11–15]. XRCC3-241Thr
genotype was associated with adverse progression-free
survival of colorectal cancer patients in one study [13].
This polymorphism was also associated with a better
prognosis for colorectal cancer patients [14].
A relatively rare polymorphism in the XRCC2 gene, a
G[A transition resulting on Arg to His substitution at
codon 188, was not found to be related with colorectal
cancer (CRC) risk in two studies [15, 16].
Recently, we have shown that the 135G[C (c. -98
G[C; rs 1801320; Genbank accession number NT 010194)
polymorphism can modify the effect of polymorphisms of
the BRCA2 and XRCC3 genes on breast cancer occurrence
[17–19].
In the present work we checked a potential inﬂuence of
this polymorphism on the Thr241Met (c. 722 C[T; rs
861539, Genbank accession number NT 026437) poly-
morphism of the XRCC3 gene and the Arg188His (c. 563
G[A; rs3218536, Genbank accession number NT 007914)
polymorphism of the XRCC2 gene on the colorectal cancer
occurrence and clinicopathological parameters in a Polish
subpopulation.
Materials and methods
Patients
Blood samples were obtained from 100 patients (36 men
and 64 women, median age 65, quartiles: 57, 75 years)
with CRC treated during the study periods (2000–2001 and
2006–2007) at The Medical University of Lodz, Depart-
ment of Gastroenterology and Internal Diseases and
Department of Surgical Oncology, N. Copernicus Hospital,
Lodz, Poland. Incidental patients consist of 90% of studied
population. All patients had histologically conﬁrmed
invasive adenocarcinoma of the colon (Supplementary
Table S1). A hundred sex- and age (±1 year)-matched
individuals hospitalized due to their complains related to
the lower gastrointestinal tract were enrolled as controls.
They were examined by colonoscopy and subsequent his-
tology of biopsies with no sign of colorectal cancer. Par-
ticularly, all controls had no macroscopic lesions of the
colon mucosa reveled in the colonoscopy. Despite this,
biopsies were taken every 10 cm along the whole colon
and rectum from apparently normal mucosa in order to
exclude individuals with early stages of mucosal dysplasia
from the control group. All patients as well as controls
were Caucasian. They accepted to cooperate and signed the
informed consent. The protocol of the study was reviewed
and approved by the Ethic Committee of the Medical
University of Lodz and the experiment was conducted with
the understanding and the consent of the human subject.
Genotype determination
Genomic DNA was prepared using the guanidine-isothio-
cyanate method as described previously [18]. The poly-
morphisms were genotyped with restriction fragment
length polymorphism polymerase chain reaction (RFLP-
PCR). RAD51 genotyping was analysed by ampliﬁcation of
a 157-bp region surrounding the 135th nucleotide. This
region contains a single MvaI site that was abolished in the
C135C variant. Wild type alleles were digested by MvaI
(Fermentas, Vilnius, Lithuania) producing 86 and 71 bp
length products. The C135C variant of RAD51 was not
digested by the enzyme, giving a single 157 bp PCR
product. PCR was performed in a MT Research, INC
thermal cycler with the following primers: 50-TGGGAA
CTGCAACTCATCTGG-30 and 50-GCGCTCCTCTCTCC
AGCAG-30 at a ﬁnal Mg
2? concentration of 1.5 mM and
annealing temperature 53C. After overnight digestion with
the enzyme, the samples were separated onto a 8% poly-
acrylamide gel. The Thr241Met polymorphism of the
XRCC3 was determined using the following primers: sense,
50-GCCTGGTGGTCATCGACTC-30; antisense, 50-ACAG
GGCTCTGGAAGGCACTGCTCAGCTCACGCACC-30.
The 136 bp PCR product was digested overnight with 3U of
the restriction enzyme NcoI. The homozygous Thr/Thr
genotype produced 39 and 97 bp fragments, heterozygous
genotype three fragments: 136, 97 and 39 bp and the homo-
zygous Met/Met genotype produced one 136 bp fragment.
Restriction fragments were analysed on 3% agarose gels
stained with ethidium bromide.
The Arg188His polymorphism of the XRCC2 was
determined using the following primers: sense, 50-TGTAG
TCACCCATCTCTCTGC-30; antisense, 50- AGTTGCTGC
CATGCCTTACA-30. The 290 bp PCR product was
digested overnight with 3U of the restriction enzyme HphI.
The homozygous His/His genotype produced 148 and
142 bp fragments, heterozygous genotype three fragments:
290, 148 and 142 bp and the homozygous Arg/Arg geno-
type produced one 290 bp fragment. Restriction fragments
were analysed on 8% polyacrylamide gels stained with
ethidium bromide. We identiﬁed the product of particular
reaction by comparing them with standards. We have
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123chosen representative pictures of gels. Examples of gels are
given on Fig. 1.
Statistical analysis
Statistical analysis was performed using STATISTICA 8.0
package (Statsoft, Tulusa, USA). Distributions of geno-
types and alleles between groups were tested using Fisher’s
exact test. A linkage between SNP, cancer and clinico-
pathological parameters was accessed by the unconditional
logistic regression (quasi-Newton method). For each SNP,
odds ratio (OR) (single stage odds ratio for Duke’s and
TNM staging) was estimated. Wild type alleles or addi-
tional homozygous variants were used as reference groups.
The Peto method was used for estimating odds ratios in
cases with no events in one or both groups. Moreover, ORs
for colorectal cancer were estimated in association with
combinations of each two genotypes, deﬁned on the basis
of three SNPs in the XRCC3, XRCC2 and RAD51 genes.
OR for each combination was calculated with homozygous
wild type variants combination as the reference. All tests
were two tailed. In all tests P values of less than 0.05 were
considered statistically signiﬁcant.
Results and discussion
We categorized all DNA samples according to the poly-
morphic variants and cancer occurrence and further in the
case of cancer patients—also according to clinicopatho-
logical parameters. Table 1 displays the distribution of
genotypes of the 135G[C, Thr241Met and Arg188His
polymorphisms. Among the controls, all genotype distri-
butions did not differ signiﬁcantly (P[0.05) from those
expected by the Hardy–Weinberg equilibrium. The fre-
quencies of genotypes of the Arg188His and Thr241Met
polymorphisms did not differ signiﬁcantly between patients
and controls. Using the logistic regression we did not ﬁnd
any association between these polymorphisms and colo-
rectal cancer occurrence. Our results on the association
between the Thr241Met polymorphism of the XRCC3 gene
and colorectal cancer are in agreement with recent meta-
analysis performed on 3,183/3,926 cases/controls [20]. In
case of the 135G[C polymorphism of RAD51 gene we
found statistically signiﬁcant differences among cases and
controls. Colorectal cancer patients had lower frequency of
C/C genotype (P\0.0001, statistical power 100%). This
protecting effect was indicated also by odds ratio analysis
(OR = 0.06, 95% CI 0.02–0.22). The current results on the
association of the 135G[C polymorphism of the RAD51
gene and colorectal cancer are in agreement with our
preliminary work [21]. In the current work we added
polymorphisms in two different genes, which enabled us to
study the role of gene–gene interaction in colorectal can-
cer. Moreover, the control group was more age-homoge-
nous than that in the preliminary research, which allowed
us to decrease potential variation in the efﬁcacy of DNA
repair related to age. Differences in effectivity of DNA
repair processes resulting from naturally occurred poly-
morphisms can affect the cancer risk [22–25]. Polymorphic
genes of DNA repair are in great part included to low
penetrance genes, which means that single gene product
most often slightly affects the disease occurrence risk, but
accumulation of changed alleles can have essential sig-
niﬁcance for its development. The combined effect of
Fig. 1 Representative PCR-RELP analyses on 8% polyacrylamide
gel containing ethidium bromide. PCR-RELP band sizes are indicated
on the right of panel. a The 135G[C polymorphism of the RAD51
gene. Lane M, DNA marker 25 bp (Fermentas); lanes 1, 3 and 6 the
G/G homozygote; lane 2 the C/C homozygote; lanes 4 and 5 the G/C
heterozygote. b The Arg188His polymorphism of the XRCC2 gene.
Lane M, DNA marker 100 bp (Fermentas); lanes 1 and 2 the His/His
homozygote; and lanes 3, 4 and 6 the Arg/Arg homozygote; lane 5
the Arg/His heterozygote. c The Thr241Met polymorphism of the
XRCC3 gene. Lane M, DNA marker 25 bp (Fermentas); lanes 1–4 the
Thr/Met hetrozygote; lane 5 the Thr/Thr homozygote; lane 6 the Met/
Met homozygote
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123investigated XRCC2, XRCC3 and RAD51 polymorphisms
on colorectal cancer occurrence has not been investigated,
yet. The design of the study enabled us to investigate
several gene–gene interactions in the context of general
relationship between a gene and its structural analogues.
Moreover, we performed our study on an ethnically
homogenous population, which may contribute to our
knowledge on the variation of genotype-phenotype rela-
tionship dependence on the population.
The frequencies of combined genotypes of XRCC2,
XRCC3 and RAD51 genes are displayed in Supplementary
Table S2. We found statistically signiﬁcant differences
between distribution of combined genotypes for colorectal
cancer patients and control groups. Odds ratio analysis for
a combination of the Arg188His polymorphism of XRCC2
with the 135G[C polymorphism of RAD51 indicates pro-
tecting role of the C/C homozygous genotype against
colorectal cancer in a Polish population (OR = 0.03; 95%
CI 0.00–0.26, P\0.0001; statistical power 99.9%).
Additional results were obtained for the combination of the
Thr241Met polymorphism of the XRCC3 gene and
135G[C polymorphism of RAD51 gene (OR = 0.07; 95%
CI 0.00–0.56, P = 0.0021; statistical power 95.8% for
Thr241Thr and C135C genotype and OR = 0.13; 95% CI
0.03–0.61; statistical power 93.6% for Thr241Met and
C135C genotype).
Combination of variant homozygous His188His geno-
type of XRCC2 gene with wild type variants of both XRCC3
and RAD51 polymorphisms increased the risk of colorectal
cancer occurrence (OR = 12.4; 95% CI 1.63–94.9, P =
0.0259; statistical power 38.7% and OR = 5.88; 95% CI
1.21–28.5, P = 0.0391; statistical power 70.1%, respec-
tively). This effect was also found for variant genotype of
the XRCC3 polymorphism in combination with wild type
homozygous genotype of the XRCC2 polymorphism
(OR = 5.70; 95% CI 1.10–29.5, P = 0.0391; statistical
power 52.4%).
Next, we divided colorectal cancer patients into groups
depending on Duke’s and TNM staging status. We did not
found any relation between any group and polymorphism
in the single stage OR analysis (Table 2). To our knowl-
edge it is the ﬁrst study linking clinical parameters of
colorectal cancer with XRCC2, XRCC3 and RAD51 poly-
morphisms.
We performed our study on relatively small populations
of both patients and controls and we do not consider our
results as deﬁnitive. Instead, they may be an important
indicator for a larger cohort study, leading to establishing
some more solid evidence. At present, we are unable to
give a straight interpretation of some of our results. For
example the XRCC2 Met241Met genotype was not asso-
ciated with the occurrence of colon cancer, but it was
associated with both increased risk in combination with
XRCC3 Arg188Arg genotype and a decreased risk in
combination with the RAD51 C135C genotype. This was
probably due to a complex interaction between these
polymorphisms, underlined by the mechanism requiring
further studies.
Double strand DNA breaks are the most dangerous DNA
damage. They occurred directly in cells as the result of
endogenous and exogenous processes or as a result of a
conversion of single strand breaks [26]. Unrepaired can
result in ampliﬁcation or loss of genetic material which can
result in neoplastic transformation by activation of onco-
genes, inactivation of suppressor genes or loss of hetero-
sigosity. It can be result of decrease of HRR ﬁdelity or
switch of repair over less correct process of non homolo-
gous end joining (NHEJ). It is also possible that genomic
instability resulted from defective repair of double strand
DNA breaks is an effect of increase of the gene expression
Table 1 Distribution of
genotypes and odds ratios (OR)
of the Arg188His polymorphism
of the XRCC2 gene (rs3218536)
and the Thr241Met
polymorphism of the XRCC3
gene (rs861539) and the
135G[C polymorphism of the
RAD51 gene (rs1801320) in
colorectal cancer
a Adjusted by age and sex
* Fisher’s exact test
Genotype or allele Patients number
(N = 100)
Controls number
(N = 100)
OR
a (95% CI) P value*
Arg188His P trend = 0.4448
Arg188Arg 75 84 1.00 ref.
Arg188His 18 14 1.44 (0.67–3.13) 0.4387
His188His 7 2 3.92 (0.78–19.8) 0.0934
Thr241Met P trend = 0.5203
Thr241Thr 36 50 1.00 ref.
Thr241Met 55 47 1.62 (0.91–2.93) 0.3185
Met241Met 9 3 3.40 (0.99–11.7) 0.0600
G135C P trend = 0.0002
G135G 61 36 1.00 ref.
G135C 36 35 0.60 (0.33–1.12) 0.1545
C135C 3 29 0.06 (0.02–0.22) <0.0001
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123not its reduction. The localization of the 135G[C poly-
morphism of the RAD51 gene in 5’UTR region indicates,
that this polymorphism can be related to mRNA stability
and translation. The RAD51 gene transcript occurred in two
main isoforms. Isoform I is 104 nucleotide longer, than
isoform II, which is result of alternative splicing. Lost
fragment of isoform II conteins 77% of GC base pairs [27].
This sequence favors dimensional structures that nega-
tively regulate translation [28, 29]. It seems to be possible
that isoform II has greater translation potential. The iso-
form II level is lower in cell lines with the C/C genotype of
135G[C polymorphism, therefore this genotype can be
related to lower level of RAD51 protein.
Our results led us to hypothesis that colorectal cancer
occurrence may be in part result of underexpression of
RAD51 gene. The cells with C/C genotype have low level
of RAD51 protein. In this event other proteins such as
XRCC2 and XRCC3 act in HRR process. Variant geno-
types of these proteins have decreased repair capacity thus
patients with this genotypes do not repair double strand
DNA breaks efﬁciently by HRR.
In present work we showed that the 135G[C polymor-
phism of the RAD51 can modify the colorectal cancer risk
alone as well as with association with other polymor-
phisms: the Thr241Met in XRCC3 gene and the Arg188His
in XRCC2 gene. We showed also that all investigated
polymorphisms 135G[Co fRAD51, Arg188His and
Thr241Met of XRCC3 should be simultaneously taken into
account as a part of polygenic cause of colorectal cancer
occurrence.
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